Johnson & Johnson (JNJ)

270.47
+3.33 (1.25%)
NYSE · Last Trade: Nov 20th, 5:54 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close267.14
Open270.36
Bid270.43
Ask271.00
Day's Range269.47 - 272.50
52 Week Range199.38 - 290.25
Volume11,918,606
Market Cap710.98B
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield5.360 (1.98%)
1 Month Average Volume7,648,625

Chart

About Johnson & Johnson (JNJ)

Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More

News & Press Releases

Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Carefool.com
Johnson & Johnson's $3.05 billion Halda bet is already paying off in the clinic.
Via The Motley Fool · November 19, 2026
Dow Jones Losers Today: NIKE and UnitedHealth Lead Declineschartmill.com
Via Chartmill · November 19, 2026
Dow Jones Decliners: UNH, NKE, CAT Lead Today's Sessionchartmill.com
Via Chartmill · November 19, 2026
Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System
Johnson & Johnson today announced that Memorial Hermann-Texas Medical Center in Houston, Texas will be the first hospital to install the OTTAVA™ Robotic Surgical System, representing a major milestone in the commercial launch of the company's next-generation soft-tissue robotic platform. Memorial Hermann will be the first hospital in the United States to utilize the system as part of Johnson & Johnson's early access commercial program.
By Johnson & Johnson · Via Business Wire · November 19, 2026
Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?fool.com
Johnson & Johnson's diversified MedTech and pharma mix faces off against Vertex's cystic fibrosis dominance, but their valuation gap tells a story worth weighing.
Via The Motley Fool · November 17, 2026
Johnson & Johnson (NYSE:JNJ): A Dividend Quality Case Study for Income Investorschartmill.com
Via Chartmill · November 9, 2026
2 of the Best Dividend Stocks to Buy With $5,000 in Novemberfool.com
These two dividend stocks offer reliable raises year after year.
Via The Motley Fool · November 17, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · November 17, 2026
Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenuefool.com
J&J's quarterly sales have climbed with few setbacks, while Pfizer's have swung between $13.7 billion and $17.8 billion over eight quarters.
Via The Motley Fool · November 17, 2026
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenuefool.com
Johnson & Johnson's revenue has climbed quarter after quarter, while Novo Nordisk's has stayed largely flat apart from one notable jump.
Via The Motley Fool · November 17, 2026
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., (“Ollin”) a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments. Johnson & Johnson will also enter into a separate development funding agreement with Blackstone Life Sciences (“Blackstone”) to support the Phase 3 clinical advancement of OLN324, contingent upon acquisition close.
By Johnson & Johnson · Via Business Wire · November 16, 2026
5 Dividend Stocks to Buy and Hold Foreverfool.com
These five stocks have proven track records of dividend growth backed by attractive businesses.
Via The Motley Fool · November 14, 2026
These 5 Dividend Aristocrats® Have Raised Payouts for Decadesfool.com
Investors worried about market turmoil may want to look at reliable dividend stocks, and these five stand out.
Via The Motley Fool · November 11, 2026
Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?fool.com
Eli Lilly's sales jumped 44.7% last year, while Johnson & Johnson's steadier profile raises a different question for cautious portfolios.
Via The Motley Fool · November 11, 2026
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?fool.com
The business has undergone major changes in recent years, and these might pay off over the medium term.
Via The Motley Fool · November 11, 2026
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boommarketbeat.com
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology
Via MarketBeat · November 11, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · November 10, 2026
Stocks Fell After the Midterms. History Says the Next 12 Months Could Be Very Differentfool.com
Keep focusing on the long term.
Via The Motley Fool · November 10, 2026
Stock Market Sell-Off: Meet the Unstoppable Vanguard ETF Obliterating the S&P 500 in 2026fool.com
Value stocks are crushing growth stocks as investors sour on the artificial intelligence trade.
Via The Motley Fool · November 10, 2026
The Buffett Indicator Is Flashing Red. These 3 Dividend Stocks Could Be Safe Havens.fool.com
The stock market is looking overvalued, according to this indicator.
Via The Motley Fool · November 10, 2026
4 Stocks I'm Not Selling Even If the Fed Keeps Raising Ratesfool.com
Some companies will perform pretty well regardless of whether or not interest rates rise.
Via The Motley Fool · November 6, 2026
2 Growth Stocks to Buy in November Without Any Hesitationfool.com
They have both outperformed the broader equity market over the long run.
Via The Motley Fool · November 5, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · November 3, 2026
Worried About an AI Bubble? This ETF Could Be the Smartest Buy Right Nowfool.com
This ETF offers a smart middle ground for investors anxious about the AI trade but who don't want to sit on the sidelines.
Via The Motley Fool · November 3, 2026
The Best Dividend Stocks to Buy With $5,000 in Novemberfool.com
AbbVie, J&J, and Medtronic remain reliable dividend plays in a rough market.
Via The Motley Fool · November 2, 2026